Behavioral Self-activation and Virtual Reality in Depression
DEPREVACT
Randomized Controlled Study of the Efficacy of Behavioral Self-Activation Through Virtual Reality in the Treatment of Depression
1 other identifier
interventional
80
1 country
1
Brief Summary
Depression is a major handicap in daily life and is often treated by behavioral activation (CA), including the Brief Behavioral Activation Treatment for Depression (BATD).The CA principle is to set up activities, in keeping with the values of the individual. Other tools associated with the CA deserve to be explored as virtual reality (VR), which offers scenarios and sensations similar to real life and a sense of life. in a safe and controlled environment, with the support of the therapist.The main objective is to compare the effectiveness of the program "BATD with RV" versus "BATD without RV" on the intensity of the depressive symptomatology and CA in everyday life. Methodology: This is a randomized, blinded study. Inclusion criteria are: 18 to 70 years old; unipolar depression diagnosis; Showing a score of ≥ 17 on the BDI-II. 80 subjects will be recruited over 24 months and randomized into 2 groups: 1) intervention group program BATD in VR; 2) BATD program intervention group without RV, lasting 45 minutes. Judgment Criteria: The effectiveness of the intervention will be evaluated by the BDI-II scale and the Behavioral Activation for Depression Scale (BADS). Outcomes: A new management of depression (AC with RV) to improve the quality of life of the patient; proof of its effectiveness; a generalization of this care; and recognition of its effectiveness in the scientific community.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable depression
Started Nov 2019
Longer than P75 for not_applicable depression
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
July 25, 2018
CompletedFirst Posted
Study publicly available on registry
August 8, 2018
CompletedStudy Start
First participant enrolled
November 29, 2019
CompletedPrimary Completion
Last participant's last visit for primary outcome
February 21, 2026
CompletedStudy Completion
Last participant's last visit for all outcomes
June 7, 2026
ExpectedMarch 22, 2024
March 1, 2024
6.2 years
July 25, 2018
March 21, 2024
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Evolution of depression
Beck Depression Inventory version II (BDI-II; depression) ; decrease BDI-II score between 0 and 6 months.
0 and 6 months
Secondary Outcomes (7)
Evolution of depressive symptoms
0, 3 and 6 months
Evolution of depression
0 and 3 months
Life quality
3 and 6 months
Physical fatigue
3 and 6 months
Number of activities
3 and 6 months
- +2 more secondary outcomes
Study Arms (2)
Efficacy of Behavioral Self-Activation with virtual reality
EXPERIMENTAL10 individual sessions of the Brief Behavioral Activation Treatment for Depression (BATD) program, lasting one hour, at the start of treatment, then half an hour thereafter, once a week \+ virtual reality activities of the session 4 to 9 lasting half an hour.
Efficacy of Behavioral Self-Activation without virtual reality
SHAM COMPARATOR10 individual sessions of the Brief Behavioral Activation Treatment for Depression (BATD) program, lasting one hour, at the start of treatment, then half an hour thereafter, once a week.
Interventions
Efficacy of Behavioral Self-Activation with virtual reality
Efficacy of Behavioral Self-Activation without virtual reality
Eligibility Criteria
You may qualify if:
- Adults aged 18 to 70,
- Having a diagnosis of unipolar depressive disorder characterized (diagnostic criteria of depression of DSM-V),
- Primary depression and not secondary to another disorder (eg social phobia, OCD, severe personality disorder, ASD, TCA, ect.)
- Showing a score greater than or equal to 17 points on the IDB-II,
- Followed by a psychiatrist from the University Hospital of Montpellier or a liberal,
- Can read, understand and speak French,
- To be affiliated or beneficiary of a social security scheme.
- Collection of informed consent.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- University Hospital, Montpellierlead
- C2carecollaborator
Study Sites (1)
University Hospital of Montpellier
Montpellier, 34295, France
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Delphine CAPDEVIELLE, MD, PhD
University Hospitals of Montpellier, France
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
July 25, 2018
First Posted
August 8, 2018
Study Start
November 29, 2019
Primary Completion
February 21, 2026
Study Completion (Estimated)
June 7, 2026
Last Updated
March 22, 2024
Record last verified: 2024-03
Data Sharing
- IPD Sharing
- Will not share